Retrospective Review of Esophageal Cancer at MSKCC

NCT ID: NCT05706558

Last Updated: 2025-09-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

4000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-12-13

Study Completion Date

2026-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Residual tumor at the proximal or distal margin after esophagectomy is a known prognostic factor for poor survival outcomes in patients with esophageal cancer; however, the significance of the circumferential resection margin (CRM) remains controversial. In this study, the investigators sought to evaluate the prognostic significance of the CRM in patients with esophageal cancer undergoing resection.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Esophageal Cancer Esophagus Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Circumferential resection margin (CRM)

Participants will have a diagnosis of esophageal carcinoma and residual tumor \>1 mm from the CRM

Esophagectomy

Intervention Type PROCEDURE

Esophagectomy

Circumferential resection margin (CRM)-close

Participants will have a diagnosis of esophageal carcinoma and residual tumor \>0-1 mm from the CRM

Esophagectomy

Intervention Type PROCEDURE

Esophagectomy

Circumferential resection margin (CRM)+

Participants will have a diagnosis of esophageal carcinoma and residual tumor at the surgical CRM

Esophagectomy

Intervention Type PROCEDURE

Esophagectomy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Esophagectomy

Esophagectomy

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed esophageal adenocarcinoma (EAC) or esophageal squamous cell carcinoma (ESCC) undergoing esophagectomy
* Pathologic staged T3 tumors (pT3)

Exclusion Criteria

* Pathologic staged T0-2 (pT0-2) or T4 tumors (pT4)
* Patients with histologic types other than EAC or ESCC, dysplasia or carcinoma in situ without tumor invasion,
* Patients undergoing salvage esophagectomy
* Evidence of distant metastatic disease
* Patients with a positive proximal or distal margin
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Memorial Sloan Kettering Cancer Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Daniela Molena, MD

Role: PRINCIPAL_INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Daniela Molena, MD

Role: CONTACT

212-639-3870

James Isbell, MD

Role: CONTACT

212-639-6247

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Daniela Molena, MD

Role: primary

212-639-3870

Related Links

Access external resources that provide additional context or updates about the study.

http://www.mskcc.org

Memorial Sloan Kettering Cancer Center

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

16-1631

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.